Sailfish Royalty Corp. announced a non-binding letter of intent with Mako Mining Corp. to purchase refined gold over 20 years, enabling Sailfish to pay a gold-linked dividend equivalent to one ounce of gold annually per 18,000 shares, plus a special $1 per share dividend after closing. The deal involves issuing 70 million shares to Mako, which will hold about 48.54% of Sailfish post-transaction. This agreement aims to increase shareholder exposure to gold prices and set a foundation for future gold-linked dividend transactions. Completion depends on regulatory and shareholder approvals, with further details to follow upon signing a definitive agreement.
Sailfish Royalty Corp.'s new gold purchase agreement is notable alongside today's market breadth where 63 of 150 US stocks on Pluang rose and 81 fell. For readers following US stocks, here is Pluang's market snapshot as of Sep 14, 2026 18:52 WIB: Intel Corp (INTC) traded at USD 96.10 with a 1-day change of -6.64%, Micron Technology (MU) at USD 918.24 down 5.85%, and Advanced Micro Devices (AMD) at USD 486.75 down 5.69%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
